View Older Stories View More Recent Stories
-
Citius Pharmaceuticals (CTXR) Misses Q2 EPS by 11c
-
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
-
Citius Pharmaceuticals (CTXR) PT Lowered to $4 at H.C. Wainwright
-
Citius Pharmaceuticals (CTXR) Announces 1.74M Share Offering at $1.15/sh
-
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
-
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
-
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
-
Citius Pharmaceuticals (CTXR) Prices 743K Share Offering at $4.035/sh
-
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Highlight LYMPHIR Commercial Launch Planned for H1 of 2025
-
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
-
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval
-
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
-
Citius Pharmaceuticals (CTXR) Announces 1-for-25 Reverse Stock Split
-
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
-
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Prices 12M Share Offering at $0.25/sh
-
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report Prelim Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR
-
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer
-
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
-
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
Citius Pharmaceuticals, Inc. (CTXR) Misses Q3 EPS by 1c
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
-
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
-
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
-
Citius Pharmaceuticals (CTXR) Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology
-
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
-
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
-
Biopharma Stocks Transformative Innovation for the Future of Health
-
Citius Pharmaceuticals (CTXR) Details Near-Term Milestones for Late-Stage Candidates
-
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
-
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals (CTXR) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
-
Citius Pharmaceuticals (CTXR) Halted, News Pending
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
-
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
